AstraZeneca's Lynparza gets EU nod as first-line ovarian cancer maintenance treatment

(Reuters) - British drugmaker AstraZeneca Plc on Tuesday said its cancer medicine Lynparza was approved as a first-line maintenance treatment for a type of advanced ovarian cancer by the European Commission, following a panel's consent in April. Lynparza, being jointly developed by AstraZeneca along with U.S. drugmaker Merck & Co, can now be used in patients who are in response following chemotherapy for BRCA-mutated ovarian cancer in Europe, AstraZeneca said.BRCA genes are responsible for..